Evidence map›Paper›PMID 35235742›Full record

ArticleDiabetes & metabolism journal2021

Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines.

Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & metabolism journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 1 country.

Soo Jin Yun *Department of Endocrinology and Metabolism, Kyung Hee Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
In-Kyung Jeong *Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
Jin-Hye ChaOutcomes Research/Real World Data Team, Viatris Korea, Seoul, Korea.
Juneyoung LeeDepartment of Biostatistics, Korea University College of Medicine, Seoul, Korea.
Ho Chan ChoDepartment of Endocrinology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.
Sung Hee ChoiDepartment of Endocrinology and Metabolism, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
SungWan ChunDepartment of Endocrinology and Metabolism, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
Hyun Jeong JeonDepartment of Endocrinology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Ho-Cheol KangDepartment of Endocrinology and Metabolism, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Sang Soo KimDepartment of Endocrinology and Metabolism, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
Seung-Hyun KoDepartment of Endocrinology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Gwanpyo KohDepartment of Endocrinology and Metabolism, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea.
Su Kyoung KwonDepartment of Endocrinology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
Jae Hyuk LeeDepartment of Endocrinology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.
Min Kyong MoonDepartment of Endocrinology and Metabolism, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Junghyun NohDepartment of Endocrinology and Metabolism, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Cheol-Young ParkDepartment of Endocrinology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sungrae KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
Korea University · KRPusan National University Hospital · KRChonnam National University Hwasun Hospital · KRChungbuk National University Hospital · KRInje University Ilsan Paik Hospital · KRJeju National University Hospital · KRKangbuk Samsung Hospital · KRKeimyung University · KRKosin University Gospel Hospital · KRKyung Hee University · KRKyung Hee University Hospital at Gangdong · KRSeoul National University · KRSeoul National University Bundang Hospital · KRSoonchunhyang University · KRThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe evaluated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients with type 2 diabetes mellitus (T2DM) according to up-to-date Korean Diabetes Association (KDA), European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS), and American Diabetes Association (ADA) guidelines.

methodsThis retrospective cohort study collected electronic medical record data from patients with T2DM (≥20 years) managed by endocrinologists from 15 hospitals in Korea (January to December 2019). Patients were categorized according to guidelines to assess LDL-C target achievement. KDA (2019): Very High-I (atherosclerotic cardiovascular disease [ASCVD]) <70 mg/dL; Very High-II (target organ damage [TOD], or cardiovascular risk factors [CVRFs]) <70 mg/dL; high (others) <100 mg/dL. ESC/EAS (2019): Very High-I (ASCVD): <55 mg/dL; Very High-II (TOD or ≥3-CVRF) <55 mg/dL; high (diabetes ≥10 years without TOD plus any CVRF) <70 mg/dL; moderate (diabetes <10 years without CVRF) <100 mg/dL. ADA (2019): Very High-I (ASCVD); Very High-II (age ≥40+ TOD, or any CVRF), for high intensity statin or statin combined with ezetimibe.

resultsAmong 2,000 T2DM patients (mean age 62.6 years; male 55.9%; mean glycosylated hemoglobin 7.2%) ASCVD prevalence was 24.7%. Of 1,455 (72.8%) patients treated with statins, 73.9% received monotherapy. According to KDA guidelines, LDL-C target achievement rates were 55.2% in Very High-I and 34.9% in Very High-II patients. With ESC/EAS guidelines, target attainment rates were 26.6% in Very High-I, 15.7% in Very High-II, and 25.9% in high risk patients. Based on ADA guidelines, most patients (78.9%) were very-high risk; however, only 15.5% received high-intensity statin or combination therapy.

conclusionAccording to current dyslipidemia management guidelines, LDL-C goal achievement remains suboptimal in Korean patients with T2DM.

Indexed as

AtherosclerosisDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLHumansMaleMiddle AgedRepublic of KoreaRetrospective StudiesCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLDiabetes mellitus, type 2DyslipidemiasGuidelineHydroxymethylglutaryl-CoA reductase inhibitors

Identifiers

PMID35235742
PMCPMC9171162
OpenAlexW4214879075

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.